ORMP on Nasdaq

Oramed Pharmaceuticals

Logo: Oramed Pharmaceuticals, Public domain, via Wikimedia Commons4

Pharmaceutical company of Israel

Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

2006Founded1

Compare with Sagimet Biosciences Inc., Cocrystal Pharma, Inc. or Lipocine Inc., or pick any stock.

  • TickerORMP on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersNew York City1
  • Founded inUnited States1
  • Websitewww.oramed.com
  • Legal formlimited company, public company1
  • Listed onNasdaq, Tel Aviv Stock Exchange (ORMP), Nasdaq (ORMP)1
  • Incorporated inDE5
  • Business address1185 Avenue Of The Americas, 3Rd Floor, New York, Ny 100365
  • Filer categoryNon-accelerated filer, Smaller reporting company5

See how the biggest companies compare on our leaderboards

Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

0.7%Gross margin7
-754.4%Operating margin7
3202.5%Net margin7
32.1%Return on equity7
-$9.2MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$2.0M
  • Research and development8¢$6.4M
  • Income tax14¢$11.3M
  • Profit76¢$64.0M

Out of $2.0M in revenue.7

Financial statements

Revenue8910117$2.0M in 2025−26% since 2019
0$1.0M$2.0M$3.0M2019: $2.7M$2.7M20192020: $2.7M$2.7M2020+0%2021: $2.7M$2.7M2021−0%2022: $2.7M$2.7M2022+0%2023: $1.3M$1.3M2023−50%2025: $2.0M$2.0M2025+49%
Operating income8910117-$15.1M in 2025+3% since 2019
-$60.0M-$40.0M-$20.0M02019: -$14.6M-$14.6M20192020: -$11.8M-$11.8M2020−20%2021: -$24.2M-$24.2M2021+106%2022: -$40.6M-$40.6M2022+68%2023: -$15.8M-$15.8M2023−61%2024: -$12.8M-$12.8M2024−19%2025: -$15.1M-$15.1M2025+18%
Net income8910117$64.0M in 2025
-$50.0M0$50.0M$100.0M2019: -$14.4M-$14.4M20192020: -$11.5M-$11.5M2020−20%2021: -$23.0M-$23.0M2021+100%2022: -$36.6M-$36.6M2022+59%2023: $5.1M$5.1M20232024: -$19.1M-$19.1M20242025: $64.0M$64.0M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
REVENUES$2.0M
COST OF REVENUE-$2.0M
GROSS PROFIT$13.0K
RESEARCH AND DEVELOPMENT EXPENSES-$6.4M-$6.3M
GENERAL AND ADMINISTRATIVE EXPENSES-$8.7M-$6.5M
OPERATING LOSS-$15.1M-$12.8M
OTHER INCOME, NET$958.0K
INTEREST EXPENSES (note 12)-$853.0K
FINANCIAL INCOME (LOSS), NET (note 17)$89.5M-$2.3M
INCOME (LOSS) BEFORE TAX EXPENSES$75.3M-$15.9M
TAX EXPENSES-$11.3M-$3.2M
NET INCOME (LOSS)$64.0M-$19.1M
NON-CONTROLLING INTERESTS-$34.0K-$43.0K
COMPANYS STOCKHOLDERS$64.0M-$19.1M
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)$1.53-$0.48
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)$1.50-$0.48
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)41.4M shares40.9M shares
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)42.4M shares40.9M shares

Compare Oramed Pharmaceuticals with another company

The story

Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.

From Wikipedia’s article on Oramed, shared under CC BY-SA 4.0.6

Leadership

Who has led Oramed Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nadav Kidron2007–now

President

  1. Nadav Kidron2007–now

Chief financial officer

  1. George Drazenovic2006
  2. Alex Weber2007
  3. Chaime Orlev2008–2009
  4. Yifat Hen Zommer2009–2017
  5. Hilla Eisenberg2017–2019
  6. Avraham Gabay2019–2021
  7. David Silberman2021–2024

Chief operating officer

  1. Joshua Hexter2013–now
2010201520202025
Board members and other officers (20)

Products and brands

Product pipeline

Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.

In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.

In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.

In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.

Read the full text

In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.

On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.

Subsidiaries

OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.

From Wikipedia’s article on Oramed, shared under CC BY-SA 4.0.6

Former names

  • Integrated Security Technologies, Inc.Jun 14, 2004 to Apr 10, 20065
  • IGUANA VENTURES LTDNov 29, 2002 to Jun 10, 20045

Timeline

  1. Aug 3, 2007New chief executive Nadav Kidron becomes CEO1
  2. Apr 10, 2006Went public Listed on NASDAQ1
  3. 2006Founded Founded in United States1

Filings

234 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 64 major events, 120 insider forms, 8 large holders, 20 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 1, 2026144 EDGAR
  4. Oct 1, 2026144 EDGAR
  5. Sep 25, 20264 EDGAR
  6. Sep 25, 20264 EDGAR
  7. Sep 25, 20264 EDGAR
  8. Sep 25, 20264 EDGAR
  9. Sep 17, 20268-K CURRENT REPORT EDGAR
  10. Aug 14, 2026SCHEDULE 13G/A EDGAR
  11. Aug 10, 202610-Q QUARTERLY REPORT EDGAR
  12. Aug 3, 2026ARS EDGAR
  13. Aug 3, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  14. Aug 3, 2026DEF 14A PROXY STATEMENT EDGAR
  15. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Jul 1, 2026144 EDGAR
  18. Jul 1, 2026144 EDGAR
  19. Jun 30, 20268-K CURRENT REPORT EDGAR
  20. Jun 29, 2026SCHEDULE 13G/A EDGAR

The 234 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 8 such filings since October 2021:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Jun 29, 2026SCHEDULE 13G/A
  3. May 15, 2026SCHEDULE 13G
  4. Feb 9, 2026SCHEDULE 13G/A
  5. Aug 28, 2025SCHEDULE 13D/A
  6. Feb 13, 2025SCHEDULE 13G/A
  7. Sep 16, 2024SC 13G
  8. Mar 22, 2024SC 13D

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 84. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mercer Global Advisors Inc /adv3,810,540$18.3M0.0%+1,900,000
Aquamarine Financial (Cayman) Ltd2,512,175$12.1M0.7%+399,863
Gem Investment Advisors, LLC1,998,802$9.6M5.9%+358,733
BlackRock, Inc.1,608,111$7.7M0.0%+1,515,919
Murchinson Ltd.1,290,294$6.2M3.0%−25,000
BML Capital Management, LLC866,269$4.2M2.4%−2,300,962
Boothbay Fund Management, LLC578,638$2.8M0.1%−22,078
Geode Capital Management, LLC500,690$2.4M0.0%+476,408
Goldman Sachs Group Inc253,293$1.2M0.0%New
State Street Corp242,100$1.2M0.0%New
Rathbones Group PLC233,018$1.1M0.0%−233,018
Vanguard Portfolio Management LLC229,882$1.1M0.0%New
Dimensional Fund Advisors LP202,609$973.8K0.0%+44,400
Northern Trust Corp184,920$889.5K0.0%New
Renaissance Technologies LLC183,800$884.1K0.0%+36,100
Wells Fargo & Company/mn166,000$798.5K0.0%+8,414
Bank Of America Corp /de/150,694$724.8K0.0%+4,542
Strs Ohio133,800$643.6K0.0%New
Jane Street Group, LLC113,349$545.2K0.0%+60,809
O'shaughnessy Asset Management, LLC102,962$495.2K0.0%−13,401
Marshall Wace, Llp101,953$490.4K0.0%−157,658
Hillsdale Investment Management Inc.89,300$429.5K0.0%−8,000
Ritholtz Wealth Management84,347$405.7K0.0%−71,132
Charles Schwab Investment Management Inc83,634$402.3K0.0%New
Bank of New York Mellon Corp79,255$381.2K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 10, 2025Brad KnottRepublican, HouseSale$15,001 - $50,000−41.9%Report
Jan 14, 2022Andrew R. GarbarinoRepublican, HouseSale$1,001 - $15,000+128.2%Report
Oct 1, 2021Andrew R. GarbarinoRepublican, HousePartial sale$1,001 - $15,000+157.8%Report
Apr 23, 2021Andrew R. GarbarinoRepublican, HouseBuy$1,001 - $15,000−142.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44